Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  • Arango, Celso
  • Baeza, Inmaculada
  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Lahera, Guillermo
  • Vieta, Eduard
  • Becker, Frauke
  • Dwyer, Georges
  • Bourke, Siobhan
  • Gibson, Adam
  • Gabarda-Inat, Irene
  • Álvarez-Baron, Elena
The abstract of this paper was presented at the 36th ECNP Congress 2023 (Barcelona 7-10 October) as a poster presentation with interim findings. The poster’s abstract was published in Abstracts of the 36th ECNP Congress 2023 in Neuroscience applied (Vol2, Supplement 2): https://doi.org/10.1016/j.nsa.2023.103062., [Purpose:] Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients’ health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects., [Patients and Methods:] This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis., [Results:] Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents’ daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia., [Conclusion:] The findings suggest that patients’ expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia., CA has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI22-01824.CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. IB has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI21/0391), co-financed by the European Union, Drugs National Plan (2022I053) and Fundación Alicia Koplowitz., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, Carol
  • Hoyos, Lucía de
  • Mora, Alberto
  • Díaz-Caneja, Covadonga M.
  • Andreu-Bernabeu, Álvaro
  • Costas, Javier
  • Gurriarán, Xaquín
  • Fañanas, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Vázquez-Bourgon, Javier
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Sánchez-Gistau, Vanessa
  • Moltó, Maria Dolores
  • Rivero, Olga
  • CIBERSAM consortium
  • Arango, Celso
  • González-Peñas, Javier
[Data availability] GWAS summary datasets used in this study have been downloaded from the PGC repository (https://www.med.unc.edu/pgc/download-results/). Gene expression data from brain developmental trajectories (http://www.brainspan.org/) and adult brain (https://gtexportal.org/home/) were downloaded from FUMA platform (https://fuma.ctglab.nl/). Individual genotype data for the CIBERSAM consortium samples (Spain, https://www.cibersam.es/en) used here and analytic code are available from the corresponding author upon reasonable request, since deposit of this data to a public repository is not allowed due to ethical and legal requirements at the participating centers., Previous studies have evaluated the role of the microRNA-137 (miRNA137) regulatory pathway in schizophrenia by using in silico or in vitro predicted target genes. These approaches do not capture the dynamic spatiotemporal nature of the miRNA137 regulatory pathway or tend to overestimate direct miRNA binding sites. To provide a more accurate representation of the miRNA137 pathway during human brain development, we evaluated the biological functionality of direct ex vivo miRNA137 targets previously documented in the early prenatal and adult brain. We studied the role of differential expression and genetic predisposing variation to schizophrenia and related disorders within these miRNA137 targets by gene set enrichment analyses (GSEA) and gene-set based polygenic score predictions in an independent schizophrenia case-control cohort. All results were compared to those from in silico or in vitro predicted targets. Only direct miRNA137 targets at prenatal and adult human brain displayed significant enrichments in synaptic and neuronal functions and captured the transcriptomic and genetic predisposing variation to schizophrenia. Furthermore, while adult target genes showed a more consistent enrichment in predisposing variation to schizophrenia and bipolar disorder in case/control polygenic models, prenatal target genes predicted negative symptomatology in schizophrenia patients. Our results suggest that using direct, temporally specific miRNA137 targets significantly improved the detection of biological mechanisms underlying its relationship with psychosis, clarified the association between schizophrenia and related conditions, and suggested association with specific symptomatology domains at different developmental stages of the disorder., Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182), the National Institute of Mental Health of the National Institutes of Health, Fundación Familia Alonso, and Fundación Alicia Koplowitz. González-Peñas held a Sara Borrell and a Miguel Servet grant during the development of the research from Instituto de Salud Carlos III (CD20/00118; CP24/00080-DOS). CM Díaz-Caneja has previously held a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024)., Peer reviewed